Skip to main content
OpenTrials
Enrolling by Invitation

NCT Number: NCT06924996

Efficacy and Safety of Endovascular Thrombectomy in Acute Ischemic Stroke With Posterior Circulation Large Infarct

The purpose of this study is to evaluate whether endovascular thrombectomy (EVT) combined with best medical management (BMM) leads to better functional outcomes than BMM alone in patients with acute basilar artery occlusion with posterior circulation large infarct.

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Beijing Tiantan Hospital

Beijing, Beijing Municipality, 100070, China

About this study

This study is a multicenter, prospective, cohort study that prospectively enrolled consecutive patients with acute basilar artery occlusion and large core infarction in the posterior circulation, confirmed by imaging (CTA/MRA/DSA). Written informed consent was obtained from all participants or their legal representatives prior to enrollment. Patients were divided into the best medical management (BMM) group and the endovascular thrombectomy (EVT) group according to the treatment they received. This study adhered to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18-80 years old;
  • Acute ischemic stroke in the posterior circulation, the onset of stroke (or last well known) to the enrollment time within 24 hours;
  • CTA/MRA/DSA confirmed acute basilar artery occlusion;
  • Posterior circulation large infarct: NCCT or DWI showed pc-ASPECTS ≤ 5 points, or pontine midbrain index (PMI) ≥ 3 points;
  • NIHSS score ≥10 points after the onset of the stroke and before enrollment;
  • Able to live independently before the onset of the disease (mRS score ≤2 points);
  • The subject or legal representative is able to sign the informed consent form.

Exclusion criteria

  • Intracranial hemorrhage (except microhemorrhage) on CT/MRI ;
  • CT/MRI revealed large infarction in the cerebellar hemisphere, with significant mass effect causing compression of the fourth ventricle or brainstem;
  • CT or MRI showed bilateral complete thalamic infarction;
  • Occlusion of anterior and posterior circulation arteries confirmed by CTA/MRA/DSA;
  • The presence of intracranial tumors (except for small meningiomas and cerebral aneurysms with a diameter of <3mm);
  • Patients with known or highly suspected chronic basilar artery occlusion.;
  • Known severe allergy to contrast agents (except for mild rash);
  • Refractory hypertension (defined as systolic blood pressure > 185 mmHg or diastolic blood pressure >110 mmHg) that cannot be controlled by drug therapy;
  • Known pregnant or lactating females, or positive pregnancy test before enrollment;
  • Acute cerebral infarction within 48 hours after cardiovascular and cerebrovascular intervention or major surgery (patients more than 48 hours can be enrolled).

Treatment and study plan

Endovascular Thrombectomy (EVT)

Procedure

A maximum of six attempts to retrieve the thrombus in a single vessel can be made with any Solitaire AB/FR device or aspiration. In case an atherosclerotic lesion is found underlying the occlusive lesion, angioplasty and subsequent stenting through detachment of the Solitaire device will be allowed

Primary outcomes

  1. Rate of modified Rankin scale 0-3 at 90 (±14) days after enrollment

    Time frame: 90 (±14) days

    The modified Rankin scale (mRS) ranged from 0 to 6, with a score of 0 indicating no disability, 1 no clinically significant disability, 2 slight disability, 3 moderate disability but remaining able to walk unassisted, 4 moderately severe disability, 5 severe disability, and 6 death.

Secondary outcomes

  1. Ordinal Shift analysis of mRS score at 90 (±14) days after enrollment

    Time frame: 90 (±14) days

    The modified Rankin scale (mRS) ranged from 0 to 6, with a score of 0 indicating no disability, 1 no clinically significant disability, 2 slight disability, 3 moderate disability but remaining able to walk unassisted, 4 moderately severe disability, 5 severe disability, and 6 death.

  2. Rate of mRS 0-2 at 90 (±14) days after enrollment

    Time frame: 90 (±14) days

    The modified Rankin scale (mRS) ranged from 0 to 6, with a score of 0 indicating no disability, 1 no clinically significant disability, 2 slight disability, 3 moderate disability but remaining able to walk unassisted, 4 moderately severe disability, 5 severe disability, and 6 death.

  3. Rate of Functional health status and quality of life (EuroQol Five Dimensions) at 90 (±14) days after enrollment

    Time frame: 90 (±14) days

    EuroQol Five Dimensions (EQ-5D) is a standardized instrument for measuring the general health status. Rated level can be coded as a number 1, 2, 3, 4 or 5, which indicates having no problems for 1, having some problems for 2, having moderate problems for 3, having serious problems for 4 and having extreme problems for 5

Other outcomes

  1. Mortality within 90 (±14) days

    Time frame: 90 (±14) days

    all-cause mortality

  2. Rate of Symptomatic intracranial hemorrhage (SICH)

    Time frame: 24-72 hours

    Symptomatic intracranial hemorrhage (SICH) within 24-72 hours after enrollment

Sponsors and collaborators

Lead sponsor

Feng Gao

Other

Registry information

Official study title

Efficacy and Safety of Endovascular Thrombectomy in Acute Ischemic Stroke With Posterior Circulation Large Infarct: A Multicenter, Prospective, Cohort Study

Important dates

Study start
2023
Primary completion
2025
Study completion
2025
First posted
Apr 13, 2025
Registry last updated
Apr 13, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.